This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

IQIRVO® (elafibranor) therapeutic indication1

IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.1

IQIRVO

IQIRVO

Mechanism of action

IQIRVO provides a multi-targeted approach

While the exact mechanism by which IQIRVO exerts its therapeutic effects in patients with PBC is not fully understood, it is thought that PPAR-α and PPAR-δ are key regulators of bile acid homeostasis, inflammation and fibrosis.

IQIRVO provides a multi-targeted approach

Abbreviations

PBC, primary biliary cholangitis; PPAR α/δ, peroxisome proliferator-activated receptor alpha + delta

Reference

  1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.